Valuation models
price $62.48 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused88.23 – 183.72120.4448% undervaluedDCF · Perpetuity growth · 10y77.13 – 156.80104.0540% undervaluedDCF · EBITDA exit · 5y96.72 – 106.62101.5338% undervaluedDCF · EBITDA exit · 10y82.94 – 98.7890.4831% undervaluedP/E · peers107.33 – 135.13112.4044% undervaluedP/E · own history74.78 – 112.5591.4232% undervaluedPEG—72.2113% undervaluedEV/EBITDA · peers100.42 – 164.58108.5542% undervaluedEV/Revenue · peers128.17 – 184.31163.9962% undervaluedEarnings power value23.12 – 50.0133.2588% overvaluedDividend discount43.96 – 140.0469.8611% undervaluedWall St. consensus target—65.004% belowCost of capital (WACC)—6.07%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
120.44
Bristol-Myers Squibb closed at $62.48 — undervalued by 48% vs model.
88.23the model's range183.72
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
33.25 – 163.99
Wall St. target
65.00 4% below
Below model, 1y
24 of 31 days
How it is valued
Valued asMature & stable
Low/slowing growth (~3% recent)Moderate margins (15% net margin)Strong dividend yieldHighly cyclical earningsHigh leverage (D/E 2.6x)Strong FCF yield (10.1%)
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.